Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX)’s Suzetrigine: ‘I Don’t See A Lot Of Upside Because That Was The Drug Of The Future For Vertex’
We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...
STAT21h
Cargo to lay off staff after CAR-T data show safety concerns
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher
Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. The company sells ...
Optimistic Outlook for Vertex Pharmaceuticals: Strong Performance, New Approvals, and Promising Pipeline Drive Buy Rating
Analyst Michael Yee of Jefferies maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?
Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...
AFP7h
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Is Vertex Pharmaceuticals Stock a Buy in 2025?
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
BioPharma Dive9d
Sionna, Odyssey join queue of biotechs testing investors’ IPO interest
The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...
Buy Rating for Vertex Pharmaceuticals: FDA Approval of Journavx Boosts Market Potential and Stock Price Target
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...